Tumor necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6) (TNF-α and IL-6)

Tumor necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6) are pivotal pro-inflammatory cytokines that orchestrate the body's immune and inflammatory responses (UniProt: P01375, P05231). TNF-α is primarily produced by activated macrophages and is a key mediator of systemic inflammation, capable of inducing fever, apoptotic cell death, and the production of other cytokines (PubMed: PMC2631033). IL-6 is a pleiotropic cytokine produced by various cells, including T cells and macrophages, which triggers the acute phase response and stimulates B-cell differentiation (PubMed: PMC6671630). Both cytokines are central to the pathogenesis of numerous chronic inflammatory and autoimmune conditions, such as rheumatoid arthritis, Crohn's disease, and cytokine release syndrome (StatPearls: Cytokine Release Syndrome). Consequently, they are major therapeutic targets, with several approved monoclonal antibodies and fusion proteins designed to neutralize their activity or block their receptors to alleviate disease symptoms and prevent tissue damage (NIH: Drug Record).

Other names

Tumor necrosis factorTNF-alphaCachectinInterleukin-6IL-6B-cell stimulatory factor 2BSF-2IFN-beta-2CTL differentiation factor

Monoclonal antibodies or soluble receptors bind to and neutralize the cytokines, preventing them from interacting with their respective cell-surface receptors (TNFR1/2 and IL-6R/gp130), thereby inhibiting downstream pro-inflammatory signaling pathways like NF-κB and JAK/STAT (StatPearls: TNF Inhibitors; StatPearls: IL-6 Inhibitors).